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ABSTRACT: Large individual diﬀerences in susceptibility to
arsenic-induced diseases are well-documented and frequently
associated with diﬀerent patterns of arsenic metabolism. In this
context, the role of the gut microbiome in directly metabolizing
arsenic and triggering systemic responses in diverse organs raises
the possibility that gut microbiome phenotypes aﬀect the
spectrum of metabolized arsenic species. However, it remains
unclear how host genetics and the gut microbiome interact to
aﬀect the biotransformation of arsenic. Using an integrated
approach combining 16S rRNA gene sequencing and HPLC-
ICP-MS arsenic speciation, we demonstrate that IL-10 gene
knockout leads to a signiﬁcant taxonomic change of the gut
microbiome, which in turn substantially aﬀects arsenic
metabolism.
Exposure to arsenic aﬀects large human populations world-wide, with contamination of drinking water by geological
sources of inorganic arsenic being the primary route of exposure.
Hundreds of millions of people drink water with arsenic levels
that far exceed the 10 μg/L guideline established by the World
Health Organization (WHO) and U.S. Environmental Protec-
tion Agency (EPA).1 For example, approximately 25 million
Americans are estimated to drink water from private wells with an
arsenic level above EPA guidelines.2 Arsenic exposure has been
associated with a number of diseases, such as skin, bladder, lung,
and liver cancers and diabetes as well as cardiovascular disorders
and reproductive defects.1 It is well-documented that there are
large diﬀerences in susceptibility to arsenic-induced diseases
among individuals at similar exposure levels,3 with several
underlying mechanisms, such as genetic polymorphisms,
epigenetics, and nutrition homeostasis, being proposed.
Individual susceptibility is frequently associated with diﬀerent
spectra of arsenic metabolism. The metabolic pathway of
inorganic arsenic consists of alternating reduction from
pentavalent arsenic to trivalent and oxidative methylation of
the trivalent arsenic metabolites. The six arsenic species involved
in this pathway in humans are inorganic arsenic (iAsV and
iAsIII), monomethylarsonic acid (MMAsV), monomethylar-
sonous acid (MMAsIII), dimethylarsinic acid (DMAsV), and
dimethylarsinous acid (DMAsIII). The abundance and patterns
of arsenic species have long been closely associated with toxicity
in humans exposed to arsenic, with the MMAsV/DMAsV ratio
showing a positive association with arsenic toxicity in several
studies.4
Accumulating evidence indicates that perturbations of the gut
microbiome and its functions may play an important role in the
development of human diseases.5 The essential role of the gut
microbiome in the metabolism of xenobiotics raises the
possibility that gut microbiome phenotypes aﬀect the bio-
transformation of arsenic; a few experiments have documented
this using gut microbiota from animal models or in vitro
simulators of the human intestinal microbial ecosystem.6 In
particular, our group has recently demonstrated that bacterial
infection-induced gut microbiome perturbations impact the
biotransformation of inorganic arsenic.7 The composition of the
gut microbiome is highly diverse, and this diversity can be
modulated by many factors, such as environment, diet, bacterial/
viral infection, and antibiotics. However, it remains unclear
whether host genetics deﬁne the gut microbiome and
subsequently aﬀect the metabolism of arsenic. Therefore, in
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this study, we employed a mouse model with diﬀerent gut
microbiome phenotypes driven by gene knockout to address this
question. The selection of interleukin-10 (IL-10) was based on
its function in immune response, which is intrinsically
intertwined with the gut ﬂora.8
The experimental workﬂow and detailed methods are
described in the Supporting Information and Figure S1. Brieﬂy,
the gut microbiome diﬀerence between wild-type and IL-10−/−
mice were ﬁrst determined using 16S rRNA gene sequencing
(Figure 1). Next, wild-type and knockout mice were treated with
arsenic (10 ppm in drinking water) for 4 weeks followed by
arsenic-speciation analysis using HPLC-ICP-MS to quantify
major arsenic metabolites (Figure 2). Finally, correlations
between the gut microbiome changes and altered arsenic
metabolites in urine were examined to establish the functional
impacts of gene-driven gut microbiome changes on arsenic
biotransformation (Figure 3).
Figure 1 shows the gut microbiome diﬀerence between wild-
type and knockout mice. Identiﬁed gut bacteria assigned at the
family level from 16S rRNA sequencing reads are illustrated, with
each color representing an individual bacterial family. Clearly, IL-
10 knockout induces a signiﬁcant taxonomic perturbation in the
gut microbiome of mice, with Bacteroidetes (teal) and
Firmicutes (brown) being remarkably increased and decreased,
as shown in Figure 1. Detailed information about changed gut
bacterial families is listed in Table S1. The diﬀerence in the gut
microbiome patterns arising from gene knockout is also readily
diﬀerentiated using multivariate statistical analysis, as shown by
the PCoA plot in Figure S2. The jackknifed β diversity and
hierarchical-clustering analysis via unweighted pair group
method with arithmetic mean (UPGMA) demonstrate that all
wild-type and knockout animals cluster in their own groups
(Figure S2). In addition, histological analysis revealed that gene
knockout and arsenic did not induce statistically signiﬁcant
diﬀerences between the wild-type and knockout mice with regard
to inﬂammation, edema, epithelial defects, crypt atrophy,
hyperplasia, and dysplasia in multiple regions of the colon and
liver during the experimental period (Figure S3).
We next performed arsenic-speciation analysis in urine (Figure
S4) and compared the relative abundance of measured arsenic
species to examine the impact of gene-driven gut microbiome
alterations on arsenic biotransformation. Among six arsenic
metabolites quantiﬁed, DMAsV was signiﬁcantly decreased in
urine after 4 weeks of exposure to arsenic (Figure 2A), whereas
MMAsV and iAsV were concurrently increased in the knockout
group (Figure 2B,C), suggesting that gut microbiome changes
arising from gene knockout interfere with the detoxiﬁcation of
inorganic arsenic. In addition, the ratio of MMAsV/DMAsV was
increased in knockout mice (Figure 2D), resembling those
observed in humans who are associated with higher arsenic
toxicity.9
To explore the functional correlation between the gut
microbiome phenotypes and arsenic metabolites, a correlation
matrix was generated by calculating the Pearson’s correlation
coeﬃcient (Figure S5). Clear correlations were identiﬁed
between the gut microbiome and altered arsenic species (ρ >
0.5 or < −0.5, p < 0.05) in exposed mice. Figure 3 lists several
typical gut bacterial components that are highly negatively or
positively correlated with DMAsV and iAsV. These results show
Figure 1. Gut microbiome composition proﬁles at the family level in
wild-type and knockout mice (p, phylum; c, class; o, order; and f,
family).
Figure 2. Gene-knockout-driven gut microbiome changes aﬀect arsenic
biotransformation in mice: (A) DMAsV, (B) MMAsV, (C) iAsV, and
(D) ratio of MMAsV/DMAsV.
Figure 3. Correlation plots, calculated by Pearson’s correlation
coeﬃcient, demonstrating the functional correlation between altered
gut bacteria families (relative abundance given on the y axis) and
DMAsV (A) and iAsV (B) (relative abundance given on the x axis)
(BBBBO: p_Bacteroidetes, c_Bacteroidia, o_Bacteroidales, and other;
BFBBO: p_Firmicutes, c_Bacilli, o_Bacillales, and other; BFCCD:
p_Firmicutes, c_Clostridia, o_Clostridiales, and f_Dehalobacteriaceae;
and BFCCR: p_Firmicutes, c_Clostridia, o_Clostridiales, and f_Rumi-
nococcaceae).
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that gut microbiome phenotypes driven by gene knockout
substantially alter the metabolite proﬁle of arsenic.
Previously, we have shown that bacterial infection-induced gut
microbiome perturbations alter arsenic metabolism.7 This study
further reveals that gene-knockout-driven gut microbiome
phenotypes aﬀect the biotransformation of inorganic arsenic,
highlighting the role of the interaction between host genetics and
the gut microbiome in xenobiotics metabolism. It has been
reported that there are large individual variations in the gut
microbiome and metagenomic genotypes in humans,10 with
mechanisms that have not been identiﬁed yet. In addition to
external factors, animal studies suggest that the host’s genetic
backgroundmay play a role in shaping gut-ﬂora phenotypes.11 Of
particular importance, gut microbiome phenotypes are asso-
ciated with diﬀerent individuals’ capacity to metabolize xeno-
biotics, as the gut microbiome is not only involved in direct
metabolism of compounds but also triggers systemic eﬀects
beyond the gut, such as altering diverse enzymes in the liver,
including P450s and other enzymes responsible for themetabolic
activation of xenobiotics.12 Therefore, it would provide novel
mechanistic insights into individual susceptibility to decipher
complex interactions among host genetics, gut microbiome
composition/function, and xenobiotics metabolism and sub-
sequent toxic eﬀects.
In summary, we have combined an animal model with gene-
driven gut microbiome phenotypes, 16S rRNA gene sequencing,
and HPLC-ICP-MS arsenic speciation to delineate the impact of
gut microbiome phenotypes on the biotransformation of arsenic.
Several major arsenic species were signiﬁcantly modulated by gut
microbiome changes resulting from gene knockout. These data
show that gut microbiome compositions play a role in aﬀecting
the abundance of speciﬁc toxic species, supporting the hypothesis
that gut microbiome phenotypes aﬀect the spectra of arsenic
metabolites and individual response to exposure. These ﬁndings
also emphasize the importance of host genetics in shaping the gut
microbiome. Taken together, this study serves as the ﬁrst
demonstration of interaction among host genetics, gut micro-
biome, and xenobiotics metabolism and highlights the gene-
driven gut microbiome phenotype as a potential novel risk factor
associated with individual susceptibility to diverse environmental
chemicals such as inorganic arsenic.
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